int230-6
·Code: INT230-6
int230-6: developed by 1 company · 1 clinical trial tracked.
int230-6 evidence translation
What we can confirm
1 tracked trial
What it means
Source-backed records connect int230-6 to INTS; that link alone does not prove the drug works.
What to watch
Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected
Prepared research question
How could int230-6 → INTS affect its developer, and what evidence supports the link?
Run cited research
Traceable citations · Unknowns marked
See linked entities and source evidence1 indications · 0 study sponsors
Related indications
Sarcoma,Soft Tissue
Study sponsors
No additional listed-company sponsor is linked.
Development Pipeline (1)
| Company | Phase |
|---|---|
| INTENSITY THERAPEUTICS, INC. (INTS) Sarcoma,Soft Tissue | Phase 3 |
Clinical Trials (1)
A Multicenter, Randomized, Phase 3 Study to Assess the Efficacy and Safety of INtratumorally Administered INT230-6 (SHAO, VINblastine, CIsplatin) Compared With US Standard of Care in Adults With Locally Recurrent, InoperaBLE, or Metastatic Soft Tissue Sarcomas (INVINCIBLE-3)
Primary endpoint: Overall Survival (OS)
InterventionalRandomizedopen333 targetStarted 2024-06Completion 2028-1217 sites · Canada, France, Germany, Spain…Intensity Therapeutics, Inc.
Frequently asked questions
Who is developing int230-6?
int230-6 is being developed by INTENSITY THERAPEUTICS, INC..
How many clinical trials involve int230-6?
BioSniper tracks 1 clinical trial involving int230-6.